Quesada J R, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, Gutterman J U
Am J Med. 1984 Sep;77(3):427-32. doi: 10.1016/0002-9343(84)90097-4.
Fifty-two patients with advanced cancer received sequentially escalating doses of 3 to 50 million units of recombinant DNA-produced alpha interferon by daily intramuscular injection. There were 23 patients with metastatic breast cancer, 17 patients with nodular poorly differentiated lymphocytic lymphoma, and 12 patients with multiple myeloma. Complete and partial remissions were obtained in 35 percent of patients with nodular poorly differentiated lymphoma, whereas rare activity was found in breast cancer and multiple myeloma. Dose-limiting toxicity occurred in patients receiving 36 million units or more and consisted of fatigue/asthenia, weight loss, and elevation of transaminase levels, requiring frequent interruption, reduction in dose, or cessation of treatment. Hematologic toxicity was rarely a limiting factor, but myelosuppression was severe in some patients with multiple myeloma. All toxicities were reversible on discontinuation of treatment. Antibodies to recombinant leukocyte A interferon were seen infrequently but may adversely affect therapy.
52例晚期癌症患者通过每日肌肉注射，依次接受剂量逐步递增的300万至5000万单位重组DNA产生的α干扰素治疗。其中有23例转移性乳腺癌患者、17例结节性低分化淋巴细胞淋巴瘤患者和12例多发性骨髓瘤患者。35%的结节性低分化淋巴瘤患者获得了完全缓解和部分缓解，而乳腺癌和多发性骨髓瘤患者的活性罕见。接受3600万单位或更高剂量的患者出现了剂量限制性毒性，表现为疲劳/乏力、体重减轻和转氨酶水平升高，需要频繁中断、减少剂量或停止治疗。血液学毒性很少成为限制因素，但一些多发性骨髓瘤患者的骨髓抑制严重。所有毒性在停止治疗后均可逆转。重组白细胞A干扰素抗体很少见，但可能对治疗产生不利影响。
